Cost per Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons
Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin
Tight and early HbA1c control in patients with type 2 diabetes mellitus in Spain: quantifying the social value
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimabnin Spain
Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
